The efficacy of chemotherapeutic agents may be determined by a number of different factors,
including the genotype of the tumor cell. The p53 tumor suppressor gene frequently is …

In the present study, we report our findings on the impact of p53 disruption on the sensitivity
of human cell lines to the antimitotic agents Taxol and vincristine. Comparisons of cell …

Abstract Paclitaxel (PTX), a microtubule-active agent, blocks cell proliferation by inhibiting
mitotic progression leading to mitotic and postmitotic arrest and cell death. Here we …

Nine human ovarian cancer cell lines that express wild-type (wt) or mutated p53 were used
to evaluate the cytotoxicity induced by paclitaxel. The IC50 calculated in the five mutated …

The anticancer agent paclitaxel (Taxol®) stabilizes tubulin polymerization resulting in arrest
in mitosis and apoptotic cell death. Normal human fibroblasts depleted of functional p53 by …

With the use of clonogenic survival assays, we show that wild-type p53-expressing A2780
human ovarian cell lines transfected with a dominant negative mutant p53 gene (codon 143 …

A stable transfectant (S2SN7) of p53-null SaOS-2 (human osteosarcoma) cells expressing
wild-type p53 under the tight control of a tetracycline-responsive promoter was used to study …

Paclitaxel-induced cytotoxicity, cell cycle perturbation, and apoptosis were determined in a
human ovarian cancer cell line expressing wt p53 (A2780) and in a subclone (A2780/E6) …

Paclitaxel exerts its cytotoxic effect by kinetic suppression of microtubules that block cells in
the G2/M phase of the cell cycle and trigger apoptosis. To investigate apoptosis induced by …

The efficacy of anticancer therapy is limited by the development of drug resistance. While the
role of p53 in the intrinsic sensitivity of human cancer cells to paclitaxel (PTX) remains …